Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib + HAIC-OXA vs Sorafenib + HAIC-FOLFOX in Advanced HCC
NCT03812770Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2018
- Primary completion
- Sep 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxaliplatin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression Free Survival at 12 months. Status: unknown.
02
Drugs
oxaliplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03812770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03812770.